- Home
- HKD vs TRVI Comparison
HKD vs TRVI Comparison
Compare HKD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKD
- TRVI
- Stock Information
- Founded
- HKD 2003
- TRVI 2011
- Country
- HKD France
- TRVI United States
- Employees
- HKD N/A
- TRVI N/A
- Industry
- HKD Finance: Consumer Services
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- HKD Finance
- TRVI Health Care
- Exchange
- HKD Nasdaq
- TRVI Nasdaq
- Market Cap
- HKD 656.8M
- TRVI 725.7M
- IPO Year
- HKD 2022
- TRVI 2019
- Fundamental
- Price
- HKD $1.78
- TRVI $5.95
- Analyst Decision
- HKD
- TRVI Strong Buy
- Analyst Count
- HKD 0
- TRVI 9
- Target Price
- HKD N/A
- TRVI $19.94
- AVG Volume (30 Days)
- HKD 430.8K
- TRVI 1.8M
- Earning Date
- HKD 01-01-0001
- TRVI 08-07-2025
- Dividend Yield
- HKD N/A
- TRVI N/A
- EPS Growth
- HKD 9.93
- TRVI N/A
- EPS
- HKD 0.23
- TRVI N/A
- Revenue
- HKD $20,445,000.00
- TRVI N/A
- Revenue This Year
- HKD N/A
- TRVI N/A
- Revenue Next Year
- HKD N/A
- TRVI N/A
- P/E Ratio
- HKD $7.73
- TRVI N/A
- Revenue Growth
- HKD N/A
- TRVI N/A
- 52 Week Low
- HKD $1.65
- TRVI $2.36
- 52 Week High
- HKD $5.80
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- HKD 44.03
- TRVI 48.10
- Support Level
- HKD $1.70
- TRVI $5.41
- Resistance Level
- HKD $1.85
- TRVI $6.08
- Average True Range (ATR)
- HKD 0.08
- TRVI 0.31
- MACD
- HKD 0.01
- TRVI -0.00
- Stochastic Oscillator
- HKD 40.91
- TRVI 50.23
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.